Affinity-Based Proteomics vs. Mass Spectrometry: Which is Better for Plasma Biomarker Research?
The discovery of reliable plasma biomarkers is transforming disease diagnosis, precision medicine, and drug development. Researchers now rely on advanced proteomics technologies to identify proteins associated with diseases at much lower concentrations than ever before. Among the leading technologies, affinity-based proteomics and mass spectrometry (MS) have become the most widely adopted approaches. Although both analyze proteins, they serve different purposes in biomarker research. Affinity-Based Proteomics Affinity-based proteomics uses antibodies or aptamers to selectively bind target proteins. Because of this targeted approach, researchers can detect proteins present in extremely low concentrations, making the technology ideal for plasma samples where clinically important biomarkers are often difficult to measure. Key advantages include: Exceptional sensitivity for low-abundance proteins High-throughput analysis of thousands of samples Small sample volume require...